期刊文献+

YKL-40和超敏C反应蛋白与冠心病的相关性 被引量:2

Correlation of YKL-40 and hsCRP with coronary artery disease
原文传递
导出
摘要 目的研究超敏C反应蛋白(hsCRP)和YKL-40与冠状动脉病变程度的关系。方法采用Judkins法进行冠状动脉造影,确诊冠心病259例及冠状动脉造影结果正常的对照组251例。应用酶联免疫法测定hsCRP和YKL-40浓度。冠状动脉病变分为1支病变(123例),2支病变(68例)和3支病变组(68例)。采用病例对照的方法进行研究。结果 YKL-40对冠心病易感性预测的受试者特征工作曲线(ROC)下面积(AUC)为0.671[95%可信区间(CI)为1.00-1.02;P<0.01];hsCRP对冠心病易感性预测的AUC为0.778(95%CI为1.24-1.50;P<0.01)。冠心病3支血管病变组血浆hsCRP和YKL-40水平明显高于1支、2支血管病变组(P<0.05或P<0.01);3支血管病变组血浆YKL-40水平明显高于2支血管病变组(P<0.05),而hsCRP在该两组间未见明显差异。在对体重指数(BMI)、高血压史、糖尿病史、吸烟史、高脂血症、TC、LDL-C、hsCRP和YKL-40调整后发现,hsCRP、YKL-40是冠心病最显著的独立相关危险因素(OR=1.37,95%CI为1.24-1.50,P<0.01;OR=1.01,95%CI为1.00-1.02,P<0.01)。结论 hsCRP、YKL-40与冠心病之间有显著相关性。 Objective To investigate whether the plasma high sensitive C-reactive protein (hsCRP) and YKL-40 levels were correlated with the susceptibility and severity of coronary atherosclerosis. Methods Plasma YKL-40 and hsCRP were measured by enzyme-linked immunosorbent assay in 259 cases with coronary artertery disease(CAD) and 251 cases without CAD, who were diagnosed by coronary angiography. CAD patients were assgined to three groups of A(123 cases with 1-vessel stenosis), B(68 cases with 2-vessel stenosis) and C(68 cases with 3-vessei stenosis). Results In predicting the susceptibility for CAD, the AUC of YKL-40 was 0. 671(95% CI :1.00-1.02,P〈0. 01) ,which of hsCRP was 0. 778(95%CI:1.24-1.50,P〈0. 01). Plasma levels of YKL-40 and hsCRP were higher in group C than those in groups of A and B(P〈0. 05 and P〈0. 01). Plasma YKL-40,but not hsCRP, was higher in group C than that in group B(P〈0. 05). After full adjustment of hypertension, diabetes, smoking, hypereholesterolemia, TC and LDL-C, YKL-40 and hsCRP were two independent risk factors for CAD(OR= 1.37,95 % CI: 1.24-1.50, P〈0. 01 and OR = 1.01,95 % CI= 1.00-1.02, P〈0. 01). Conclusion It is concluded that there is a close relationship between plasma levels of YKL-40 and hsCRP and the severity of CAD.
出处 《江苏医药》 CAS CSCD 北大核心 2012年第17期2043-2045,共3页 Jiangsu Medical Journal
基金 南京医科大学科技发展基金(2010NJMUZ52)
关键词 冠状动脉粥样硬化YKL-40 超敏C反应蛋白 Atherosclerosis YKL-40 High sensitive C-reactive protein
  • 相关文献

参考文献17

  • 1Libby P. Inflammation in atherosclerosis[J]. Nature, 2002, 420(6917) : 868-874.
  • 2Hansson GK. Inflammation, atheroselerosis, and coronary artery disease[J]. N Engl J Med, 2005, 352 (16): 1685-1695.
  • 3Rathcke CN, Vestergaard H. YKL-40-an emerging biomarker in cardiovascular disease and diabetes[J]. Cardiovasc Diabetol, 2009,8:61.
  • 4Boot RG, van Achterberg TA, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages [J]. Arterioscler Thromb Vasc Biol, 1999,19(3) : 687-694.
  • 5Shackelton LM, Mann DM, Millis AJ. Identification of a 38- kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as amember of a group of proteins associated with tissue remodelling[J]. J Biol Chem, 1995,270(22) : 13076-13083.
  • 6Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils[J]. Proc Assoc Am Physicians, 1998,110(4) : 351-360.
  • 7Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular eells[J]. Exp Cell Res,2003,287(1) :79-87.
  • 8Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and eaneer[J]. Dan Med Bull,2006, 53(2):172-209.
  • 9Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulinresistance and with a role in endothelial dysfunction and atheroselerosis[J]. Inflamm Res, 2006,55 (6): 221-227.
  • 10Jiang S, BaoY, Hou X, et al. Serum C-reactive protein and risk of cardiovascular events in middle-aged and older chinese population[J]. Am J Cardiol,2009,103(12):1727-1731.

同被引文献11

  • 1谢辛,苟文丽.妇产:科学[M].北京:人民卫生出版社,2013:180-181.
  • 2Estibalitz Laresgoiti-Servitje. A leading role for the immune system in the pathophysiology of preeclampsia[J]. J Leukoc Biol, 2013,94(2) : 247-257.
  • 3Mygind ND, Lversen K, Kober L, et al. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality[J]. J Intern Med,2013,273(2) :205-216.
  • 4Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factorsin diagnosis, management, and research in preeelampsia [ J ]. Hypertension,2014,63(2) : 198-202.
  • 5Svensson-Arvelund J, Ernerudh J, Buse E, et al. The placenta in toxicology. Part II: systemic and local immune adaptations in pregnancy[J]. Toxicol Pathol,2014,42(2) :327-338.
  • 6Vendrame E, Hussain SK, Breen EC, et al. Serum levels of cytokines and biomarkers for inflammation and immune activa- tion, and HIV-associated non-Hodgkin B-cell l'nphoma risk [J]. Cancer Epidemiol Biomarkers Prey, 2014,23(2) : 343-349.
  • 7Boij R, Svensson J, Nilsson-Ekdahl K, et al, Biomarkers of coagulation,inflammation, and angiogenesis are independently associated with preeclampsia [J ]. Am J Reprod Immunol, 2012,68(3) : 258-270.
  • 8孔祥,卢丹,赵群,王志学.子痫前期患者血浆YKL-40、IL-18和CRP水平变化及临床意义[J].扬州大学学报(农业与生命科学版),2013,34(3):19-22. 被引量:5
  • 9王昌敏,陈程,赵进,黄睿.急性冠脉综合征不同病程、不同疾病类型患者YKL-40、IL-35、脂联素等表达特征分析[J].标记免疫分析与临床,2018,25(9):1276-1280. 被引量:8
  • 10林美萍,王建军.微小RNA-126和微小RNA-155在冠心病合并糖耐量减低患者中的表达及阿卡波糖的干预作用[J].临床内科杂志,2019,36(2):108-112. 被引量:3

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部